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The development of cancer is a pathological process involving multiple environmental carcinogenic factors and genetic altera-
tions. For decades, cancer researchers have focused on genomic and transcriptomic analyses. The completion of the Human 
Genome Project has opened the door to the post-genome era and oncoproteomics. Proteins play a critical role in tumorigenesis 
and influence the differences between normal cells and malignant cells. This report proposes the concept that cancer is a pro-
teomic disease. This concept is based on examining protein expression profiles, post-translational modifications, and pro-
tein-protein interactions in carcinogenesis using recent advances in comparative, functional and structural proteomics. This ap-
proach provides a new way of viewing carcinogenesis, presents new clues in biomarker discovery for cancer diagnosis and 
therapy, and reveals important scientific findings and their significance to clinical applications. 
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The development of tumors is a multi-step process involv-
ing various environmental and genetic factors. Cancer is 
characterized by uncontrolled control cell growth, invasion 
and metastasis. Cancer studies using genomic and tran-
scriptomic approaches have been used for years [1]. All 
genetic information is contained in the genome as an origi-
nal template that guides protein biosynthesis, and proteins 
drive almost all the functions of the cell and determine 
phenotypes. 
Likewise, the differences between cancer cells and nor-
mal cells are in large part determined by differential protein 
expression. Therefore, it is reasonable to study the mecha-
nisms of tumorigenesis at the proteome level [2]. Along 
with the extensive application of proteomics theory and 
relevant cancer research techniques, oncoproteomics has 
been an active area of research in medical research, ena-
bling many breakthroughs. Based on combining this new 
perspective with previous achievements in the field, we 
view cancer as a proteomic disease rather than a genetic 
disease. 
1  Cancer development and proteome profiling 
A key task of oncoproteomics is to select differentially ex-
pressed proteins and determine their function. Recent stud-
ies revealed distinct differences between cancer and normal 
cells at the proteome level, and that oncoproteome compo-
nents vary at different points in time or under different con-
ditions. These observations suggest that alterations in the 
proteome are involved in cancer development and in the 
regulation of malignancy.  
A two-dimensional proteome map of human naso-
pharyngeal squamous cell carcinoma first published by Li et 
al. [3,4] found 28 proteins differentially expressed between 
normal nasopharyngeal epithelial tissue and nasopharyngeal 
carcinoma (NPC). Thirty-six proteins differentially ex-
pressed between normal nasopharyngeal epithelial tissue 
and nasopharyngeal carcinoma were laser-microdissected. 
Among the 36 proteins, the expression of stathmin, 14-3-3σ, 
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annexin I and cathepsin D was associated with TNM (Tumor, 
Node, Metastasis) stage of nasopharyngeal carcinoma [5]. 
Hsieh et al. [6] analyzed proteome dynamics using 
two-dimensional gel electrophoresis coupled to mass spec-
trometry (2-DE) and reconstructed the associated cell cycle 
networks in human hepatoma cells that give rise to Mahlavu 
hepatocellular carcinoma (HHCM). They identified 2665 
protein spots in all and the degree of global protein change 
was phase dependent, with the greatest change occurring in 
transitional phases at S/G2, G2/M, and G1/S. Further ex-
amination revealed that SP1, c-Myc, p53, YY1 and c-Jun 
acted as key transcription factors in G0/G1, G1/S, S, and 
G2/M, respectively, resulting in cell-cycle progression or 
arrest. To study the cellular and molecular mechanisms of 
Ras-mediated oncogenic transformation of ovarian epithe-
lial cells, Young et al. [7] used a proteomic approach using 
2-DE and mass spectrometry to profile two ovarian epithe-
lial cell lines, one immortalized and the other transformed 
with an oncogenic rasV12 allele. More than 30 protein tar-
gets showed significant changes between immortalized and 
transformed cell lines, where the Ras-signaling pathway 
was found to be involved in an enhanced anti-oxidation 
state. This enhanced anti-oxidation state might constitute a 
common mechanism for tumor cells to evade oxidative 
stress induced apoptosis. Smad4 is a tumor-suppressor gene 
lost or mutated in 50% of pancreatic carcinomas. A study 
using 2-DE-MS examined proteomic changes in Smad4 
knockdown (S4KD) pancreatic cancer cell lines with and 
without TGF-β stimulation. Five proteins were up-regulated 
and seven proteins were down-regulated, 10 of which were 
novel targets for TGF-β. These proteins functioned in proc-
esses such as cytoskeletal regulation, cell cycle progression, 
and oxidative stress [8]. 
Subcellular organelles are specially related to the corre-
sponding cellular functions, so it is essential to separate and 
identify cancer cell organelle proteomes under various con-
ditions to help identify tumorigenesis mechanisms. Qattan 
et al. [9] adopted quantitative, tandem mass spectrometry-     
based shotgun proteomic techniques to investigate the spa-
tial distribution of proteins in MCF-7 breast cancer cells. A 
total of 2184 proteins were identified in four major organel-
lar compartments: the cytosol, plasma membrane, endo-
plasmic reticulum, and mitochondrion. Of these proteins, 
481 were found to have a unique subcellular location and 
454 were ubiquitous. The remaining 1249 proteins were 
distributed over multiple, but not all, subcellular locations. 
These results indicate that multiple subcellular locations 
exist for proteins in processes related to breast cancer. 
Leth-Larsen et al. [10,11] identified 13 membrane proteins 
that were over-expressed and three that were under-ex-      
pressed in a metastatic versus non-metastatic cell line from 
a total of 1919 protein entries. High ecto-5′-nucleotidase 
and integrin β1 expression correlated with tumor spread or 
distant recurrence, and poor outcome within a 10-year fol-
low-up [10]. In addition, NDRG1, HLA-DRα, HLA-DRβ, 
and CD74 were associated with the ER(−)/PR(−) pheno-
type.  
The degree of cancer differentiation is not only corre-
lated with pathological phenotypes, clinical symptoms and 
prognosis, but also with proteomic alteration. Recently, Xiao 
et al. [12] performed quantitative proteomic analysis of 
flash frozen paraffin embedded (FFPE) NPC with various 
degrees of differentiation using isobaric tag for relative and 
absolute quantitation (iTRAQ) labeling, and two-dimen-      
sional liquid chromatography, tandem mass spectrometry (2D 
LC-MS/MS). Interestingly, 730 unique proteins were ac-
quired from FFPE tissues. Of these, 531 are associated with 
various cellular processes, including proliferation, cell death, 
defense response, DNA repair and carbohydrate metabolism. 
One hundred and forty-one proteins were up-regulated, 140 
down-regulated and 157 fluctuated in direction. 
At multiple steps during cancer development and progres-
sion, the proteome keeps changing. Habermann et al. [13] 
analyzed the sequential alterations of the genome, tran-
scriptome, and proteome during colorectal cancer progres-
sion and found that the expression of nine proteins de-
creased, and 32 proteins increased in proportion to cancer 
malignancy. The proteins identified played a role in cell 
cycle regulation, apoptosis and signal transduction (Figure 
1). Wu et al. [14] performed a comparative proteomic study 
on 32 cases of human bronchial epithelia, including normal, 
metaplasia, dysplasia, and carcinoma tissues. Differentially 
expressed proteins were identified between the normal and 
metaplasia groups (33 proteins), the metaplasia and dyspla-
sia groups (42), and the dysplasia and carcinoma groups 
(38). Some proteins are known to be involved in regulating 
cell proliferation, differentiation and signal transduction, 
whereas some are involved in cell-cell interaction and oth-
ers are oncogene or anti-oncogene products. In another 
study, gastric cancer was induced in 12 Wistar rats by oral 
administration of N-methyl-N′-nitro-N-nitrosoguanidine 
(MNNG) followed by evaluation of the protein expression 
patterns of matched tissues and corresponding metastases. 
Twenty-five proteins served as landmarks for comparison 
between tissues. Over-expression of HSP27 was confirmed 
by immunohistochemical analysis of human gastric cancer 
specimens and its expression correlated with the process of 
carcinogenesis and metastases [15]. Choong et al. [16] 
conducted proteomic analysis of the MCF10AT breast can-
cer model, composed of four isogenic xenograft-derived 
human cell lines that mimic different stages of breast cancer 
progression, using iTRAQ 2D-LC-MS/MS. Of more than 
1200 proteins detected, 98 represent at least 20 functional 
groups, including kinases, proteases, adhesion, calcium bind-
ing and cytoskeletal proteins exhibited significant expression 
changes. These results suggest that the MCF10AT model of 
breast cancer progression models major re-programming in 
metabolism, or the “Warburg effect”. We also validated that 
HIST1H2BM is down-regulated as breast cancer lesions 
progress. 
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Figure 1  Summary figure of genomic, transcriptional, and proteomic changes along the “adenoma-carcinoma-sequence” [13]. 
Clinical proteomics has been used to discover many 
cancer-related protein markers that are involved in tumori-
genesis and used in prognosis. Serological proteome analy-
sis was performed on human lung squamous carcinoma 
(hLSC) to identify tumor-associated antigens. Fourteen 
hLSC-associated antigens were identified and six of those 
were validated to be up-regulated in hLSC tissues, suggest-
ing potential application of these antigens in the diagnosis 
and therapy of hLSC [17]. Liu et al. [18] assessed protein 
expression differences between primary lung adenoma can-
cer with (LNM AdC) and without (non-LNM AdC) lymph 
node metastasis using a quantitative proteomic approach. 
Among the 20 differentially expressed proteins identified, 
statistical analysis indicated that over-expression of annexin 
A1, A2, and A3 was associated with increased relapse rate 
and decreased survival rate. Previous clinical proteomic 
studies have demonstrated that a single protein is insuffi-
cient as a cancer diagnostic marker and that a fingerprint 
composed of several proteins greatly enhances the sensitiv-
ity and specificity of diagnosis. For example, to detect early 
stage invasive epithelial ovarian cancer, the sensitivity of a 
multivariate model combining three biomarkers with 
CA125 (74% (95% CI, 52%–90%)) was higher than that of 
CA125 alone (65% (95% CI, 43%–84%)) at a matched 
specificity (97% (95% CI, 89%–100%)). When compared at 
a fixed sensitivity (83% (95% CI, 61%–95%)), the specific-
ity of the model (94% (95% CI, 85%–98%)) was signifi-
cantly better than that of CA125 alone (52% (95% CI, 
39%–65%)). This demonstrates that combining biomarkers 
has the potential to improve detection of early stage ovarian 
cancer [19,20]. 
Studying cancer development and progression, and iden-
tifying markers at different stages using whole cell and or-
ganelle proteomics helps reveal how cancer develops, and 
may lead to new approaches for early diagnosis and im-
proved therapy. 
2  Tumor and proteomics of post-translational 
modifications 
Post-translational modifications (PTMs) such as glycosyla-
tion, phosphorylation, and ubiquitination induce structural 
changes and play an important role in the genesis and de-
velopment of cancer. Because of the broad dynamic range 
of protein expression, accurate detection of post-transla-      
tionally modified proteins still presents a significant techni-
cal challenge. Nevertheless, development and integration of 
different methods, such as affinity-based enrichment meth-
ods, multi-dimensional separation technologies, and mass 
spectrometry show promise for post-translational pro-
teomics at a large scale [21]. 
Glycoproteins contain oligosaccharides (glycans) cova-
lently attached to polypeptide side-chains. Whelan et al. [22] 
chose the hydrazide method to specifically target, enrich, 
and identify glycosylated proteins from breast cancer cell 
membrane fractions using a LTQ Orbitrap mass spectrome-
ter. Twenty-seven N-linked glycosylation sites in 25 differ-
ent proteins were identified, including sites on epidermal 
growth factor receptor (EGFR), CD44, and the breast cancer 
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1, and early onset isoform 1 (BRCA1), which mediate 
breast cancer invasion and metastasis by regulating cell dif-
ferentiation and proliferation. Chaerkady et al. [23] used 
lectin affinity chromatography and 18O tag quantitative pro-
teomics to profile matched cancer and non-cancer hepato-
cellular carcinoma (HCC) samples. Using this approach, 
they identified and quantitated over 200 glycoproteins. One 
protein of interest was clusterin isoform 2 (apolipoprotein J), 
a sulfated glycoprotein involved in apoptosis, cell death and 
complement activation, which is a potential biomarker in-
volved in HCC metastasis. To assess the usefulness of a 
lectin microarray approach for identifying glycan profiles 
related to metastatic potential, cell lines L02 (control), 
Hep3B (no metastasis) and HCCLM3 (high metastatic po-
tential) were evaluated. Comparison of L02 with Hep3B 
showed an increase of branched complex oligosaccharide, 
high-mannose sugars, terminal fucose, T antigen of mucin, 
reduced N-acetyl glucosamine or sialyl-Tn. These structural 
changes may have implications in the characteristic change 
of hepatocellular carcinoma invasion. HCCLM3 demon-
strated increased levels of core fucose, sialic acid (mainly 
α2-3 link), N-acetyl glucosamine, bisecting N-acetylglu-       
cosamine and reduced β1-4 linked galactose. These struc-
tural changes may have implications in hepatocellular car-
cinoma metastasis [24]. 
Protein phosphorylation plays an important role in regu-
lating many processes life. Li et al. [25] identified a total of 
247 phosphoproteins containing 281 phosphotyrosine (pTyr) 
sites in Hep3B and MHCC97H (a highly metastatic HCC 
cell line). Bioinformatics analysis identified over-expressed 
phosphoproteins involved in cell motility and migration, 
protein autophosphorylation, cell-cell communication, and 
anti-apoptosis functions. These proteins play a role in a va-
riety of signaling pathways, including EGFR signaling, cy-
tokine- and chemokine-mediated signal transduction, and 
the PI3K and JAK-STAT cascades that are activated during 
HCC metastasis. Using 2-DE, 2-D Western blotting, and 
mass spectrometry, Ruan et al. [26] identified and quanti-
fied the tyrosine phosphorylation levels of 16 proteins in 
TGF-α-treated CNE2 human NPC cells. These results may 
provide new insights into EGFR phosphorylation signaling 
and have implications in molecular cancer therapy of NPC. 
Akashi et al. [27] measured the expression of 393 proteins 
in 39 human cancer cell lines (JFCR-39). Using an inte-
grated approach allowed us to identify two peaks at 11.6 
and 11.8 kD that showed significant correlations with sensi-
tivity to the PI3K inhibitor, LY294002. In addition, based 
on results from A549 cancer cells, Akashi et al. [28] pre-
dicted the presence of novel multi-phosphorylated forms of 
4E-binding protein 1 (4E-BP1), which is a downstream 
component of the PI3K/Akt/mTOR pathway and regulates 
protein synthesis. They also investigated the effect of 
ZSTK474, a novel phosphatidylinositol 3-kinase (PI3K) 
inhibitor that has little inhibitory effect on mTOR, on 
4E-BP1 phosphorylation using phospho-specific antibodies. 
Interestingly, ZSTK474 inhibited phosphorylation of Ser65, 
Thr70 and Thr37/46 in 4E-BP1, sites shown to play an im-
portant role in cancer development. 
Ubiquitination plays an important role in protein translo-
cation, metabolism, function, regulation and degradation, in 
turn regulating cell growth, proliferation, apoptosis, differ-
entiation, and tumor metastasis. Using a combination of 
immunoaffinity purification and liquid chromatogra-
phy-tandem mass spectrometry (LC-MS/MS), Vasilescu et 
al. [29] were able to identify 70 ubiquitinated proteins from 
the human breast cancer cell line MCF-7 after treatment 
with the proteasome inhibitor MG132, implicating them in 
the progression of breast cancer. Meierhofer et al. [30] used 
stable Hela cell lines expressing a tandem hexahis-
tidine-biotin tag (HB-tag) fused to ubiquitin in a two-step 
purification of the ubiquitinated proteome under fully dena-
turing conditions. They identified 669 ubiquitinated proteins, 
including 44 with all seven possible ubiquitin chain-linkage 
types. Quantitative mass spectrometry using the stable iso-
tope labeling with amino acids (SILAC) strategy in cell 
culture was used to profile cells treated with the proteasome 
inhibitor MG132. This approach should help identify ubiq-
uitinated proteins targeted to the proteasome for degradation 
and detect ubiquitination changes in response to growth 
conditions and cellular stress, all of which may play a role 
in cancer.  
In summary, various proteomic differences have been 
shown to play a role in glycosylation, phosphorylation, 
ubiquitination and other post-translational modification re-
lated to cell cycle progression, cellular proliferation and 
migration, and apoptosis during tumor development. 
3  Cancer development and protein-protein in-
teractome dynamics 
Protein-protein interactions play a central role in regulating 
the function of cells and organisms. Studies aiming to elu-
cidate interactome dynamics at different times and condi-
tions promise to be a major step towards modeling cellular 
function and behavior. A shift from a static to a dynamic 
network analysis should help elucidate the mechanisms of 
tumorigenesis [31]. 
Jonsson et al. [32] found that proteins in cancerous cells 
demonstrated an increase in the number of interacting part-
ners and contained a higher number of highly promiscuous 
structural domains (i.e., domains with a high propensity for 
mediating protein interactions). Moreover, an underlying 
evolutionary distinction existed between the two groups of 
proteins, reflecting the central roles of proteins whose muta-
tions lead to cancer. Alpha fetoprotein (AFP), for example, 
has been implicated in the development of HPC and is con-
sidered to be a diagnostic and prognostic tumor marker. The 
protein expression profiles of nine AFP-producing cell lines 
and seven non-AFP producing cell lines were generated by 
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fluorescence 2-dimensional difference gel electrophoresis 
(2D-DIGE). Multivariate analysis of six up-regulated and 
five down-regulated proteins was used to distinguish 
AFP-producing cell lines from non-AFP producing cell 
lines. Understanding their interaction could provide insight 
into the biology of AFP-producing hepatocellular carcinoma 
cells [33]. More than 50% of human cancers have a p53 
gene mutation. Hu et al. [34] and Sun et al. [35] revealed 
several p53 interacting proteins in nasopharyngeal carci-
noma cells using RNA interference, immunoprecipitation 
and proteomic techniques. These proteins took part in the 
regulation of cell cycles and gene expression programs, and 
covered several signaling pathways. As p53 interacting 
proteins, they provided important clues regarding the 
mechanisms of p53 accumulation and inactivation in NPC. 
NDRG1 is known to play important roles in both andro-
gen-induced cell differentiation and inhibition of prostate 
cancer metastasis. Tu et al. [36] identified 58 proteins that 
interacted with NDRG1 in prostate cancer cells using 
co-immunoprecipitation and mass spectrometry analysis. 
The results showed that NDRG1 bound directly to β-catenin 
and E-cadherin. Moreover, the interactome map provided 
the first road map for understanding the functions of 
NDRG1 in prostate cancer, which progresses from an an-
drogen-dependent curable stage to an androgen-inde-      
pendent incurable stage. Application of protein-level and 
peptide-level sample fractionation combined with LC-MS/ 
MS analysis enabled identification of 2235 unmodified pro-
teins representing a broad range of functional and compart-
mental classes. Nine interacting proteins (SLC3A2, PXN, 
ITGB1, ITGB2, FLNB, ITGB4, ITGAV, ITGA3, EGFR) 
were clustered according to their gene expression profiles 
across four cell lines. The epidermal growth factor receptor 
(EGFR) shared a similar transcript profile with several of 
the integrin subunits across all four cell lines. EGFR recep-
tor activation is governed by integrin mediated phosphory-
lation during cell adhesion. The up-regulation and down-      
regulation of integrin receptors may play a role in cancer 
invasion and metastasis by altering the ability of cells to 
adhere to surrounding cells and the extracellular matrix [37] 
(Figure 2). 
A series of events in the development of cancer, includ-
ing premalignant lesions, dysplasia, invasive and distant 
metastasis, are the result of multiple factors and their inter-
actions. Therefore, studies focused on the interactome and 
tumor-associated gene networks as a whole may facilitate a 
better understanding of the mechanisms of tumorigenesis, 
and thus prevention.  
In summary, the development and progression of cancer 
is closely related to abnormal protein expression, altered 
posttranslational modification, and protein interactions. In 
addition, aberrant protein alterations in cells can lead di-
rectly to malignant characteristics and oncogenic transfor-
mation. A proteomic approach to studying protein expres-
sion and signaling pathways may help scientists understand 
the mechanisms of tumorigenesis, identify new diagnostic 
markers and drugs, and provide a clinical basis for early 




Figure 2  Protein-protein interaction network of nine modified proteins from breast cancer [37]. Red indicates increased abundance and green indicates 
reduced abundance relative to the reference panel of cell lines. The “Ph” superscript indicates phosphorylation preferentially detected in the cancer cell lines  
(MDA231, BT474, MCF7) and absent in HMEC (*). 
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